• Company
• From Factive to Rolontis, commercial success or failure
• by Chon, Seung-Hyun Sep 22, 2022 06:01am

• Policy
• MOHW's advisory council to respond to US’s Bio initiative
• by Lee, Jeong-Hwan Sep 21, 2022 05:47am

• Company
• Enhertu lands in Korea...hopes rise for indication extension
• by Sep 21, 2022 05:47am

• Policy
• Domestic authorization for the Quadrivial Adjuvant Flu Vac
• by Lee, Tak-Sun Sep 21, 2022 05:47am

• Company
• RET-targeted anticancer drugs are being released in Korea
• by Whang, byung-woo Sep 21, 2022 05:47am

• Policy
• 23 items have been designated as Fast Tracks in 2yrs
• by Lee, Hye-Kyung Sep 21, 2022 05:47am

• Policy
• GOV engrossed in minimizing damage from US's Bio Initiative
• by Lee, Jeong-Hwan Sep 20, 2022 05:57am

• Company
• Influenza alert in three years
• by Chon, Seung-Hyun Sep 20, 2022 05:57am

• Policy
• 37 Tenelia's generics will soon be listed
• by Lee, Tak-Sun Sep 20, 2022 05:57am

• Policy
• NHIS negotiations complete for Erbitux·Zerbaxa·Eylea
• by Lee, Tak-Sun Sep 20, 2022 05:56am